Pyxis Oncology closes $102.8 million net offering; warrants need shareholder approval
Pyxis Oncology closed an underwritten public offering on October 1, 2026, selling 36,047,919 shares and pre-funded warrants for 1,883,121 shares, each paired with common warrants, for a combined price of $2.90 per share. The company expects net proceeds of about $102.8 million, and says its cash plus these proceeds will fund operations into the first half of 2028. The common warrants cannot be exercised until stockholders approve an increase in authorized shares, and if they are exercised, the company would receive about $162.2 million more, net of a 6% solicitation fee.
Key points
- Offering: 36,047,919 shares and 1,883,121 pre-funded warrants, with common warrants for up to 49,310,352 shares; closed October 1, 2026
- Combined public offering price of $2.90 per share; common warrants have a $3.50 exercise price
- Net proceeds of about $102.8 million; up to about $162.2 million more if all warrants are exercised, net of a 6% fee
- Warrants require a stockholder vote to increase authorized shares, with a meeting planned within 60 days of closing; the company says funds may be insufficient for the Phase 3 Headliner trial if warrants go unexercised
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.